Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RO6926496 in Healthy Volunteers
NCT02281786Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RG7345 in Alzheimer's disease (AD) (6 cohorts), sponsored by Roche. Primary endpoint: Incidence of adverse events (AEs) up to 16 weeks. Started Jan 2015; status: completed.
02
Drugs
RG7345
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02281786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281786.